Therapy of cutaneous leishmaniasis

International Journal of Infectious Diseases

Volumn 7, Issue 2, 2003, Pages 86-93

  Lee, Samuel A ^a,b   Hasbun, Rodrigo ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; ANTIMONY DERIVATIVE; CLOTRIMAZOLE; COTRIMOXAZOLE; DAPSONE; EMETINE; GAMMA INTERFERON; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; LEISHMANIA VACCINE; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; METRONIDAZOLE; MICONAZOLE; MILTEFOSINE; N ACETYL S NITROSOPENICILLAMINE; PAROMOMYCIN; PENTAMIDINE; PYRROLE DERIVATIVE; RIFAMPICIN; STIBOGLUCONATE SODIUM; TERBINAFINE;

ANEMIA; ARTHRALGIA; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; CRYOSURGERY; CRYOTHERAPY; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG TOLERABILITY; EPIDEMIOLOGICAL DATA; HUMAN; HYPERTHERMIC THERAPY; HYPOPIGMENTATION; LEISHMANIA; LIVER TOXICITY; LONG QT SYNDROME; MYALGIA; NAUSEA; NEPHROTOXICITY; PANCREAS DISEASE; PANCREATITIS; PANCYTOPENIA; PATHOGENESIS; REVIEW; SIDE EFFECT; SKIN BIOPSY; SKIN LEISHMANIASIS; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING;

EID: 0037662913     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(03)90002-6     Document Type: Review

References (64)

1. Desjeux P. Leishmania and HIV in gridlock. WHO/CTD/LEISH/98.9. Geneva: World Health Organization, 1998.
2. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24:684-703.
3. Guerin PJ, Olliaro P, Sundar S, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002; 2:494-501.
4. Mattos M, Caiza A, Fernandes O, et al. American cutaneous leishmaniasis associated with HIV infection: report of four cases. J Eur Acad Dermatol Venereol 1998; 10:218-225.
5. Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microb Rev 1997; 10:298-319.
6. Weigle KA, Labrada LA, Lozano C, Santrich C, Barker DC. PCR-based diagnosis of acute and chronic cutaneous leishmaniasis caused by Leishmania (Vianna). J Clin Microb 2002; 40:601-606.
7. Matsumoto T, Hashiguchi Y, Gomez EA, et al. Comparison of PCR results using scrape/exudates, syringe-sucked fluid and biopsy samples for diagnosis of cutaneous leishmaniasis in Ecuador. Trans R Soc Trop Med Hyg 1999; 93:606-607.
8. Berman JD. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis 1988; 10:560-586.
9. Koff AB, Rosen T. Treatment of cutaneous leishmaniasis. J Am Acad Dermatol 1994; 34:693-708.
10. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46:296-306.
11. Evans TG. Leishmaniasis. Infect Dis Clin North Am 1993; 7:527-546.
12. Deps PD, Viana MC, Falqueto A, Dietze R. Comparative assessment of the efficacy and toxicity of N-methylglucamine and BP88 sodium stibogluconate in the treatment of localized cutaneous leishmaniasis. Rev Soc Bras Med Trop 2000; 33:535-543.
13. Chulay JD, Anzeze EM, Koech DK, Bryceson DM. High-dose sodium stibogluconate treatment of cutaneous leishmaniasis in Kenya. Trans R Soc Trop Med Hyg 1983; 77:717-721.
14. Belazzoug S, Neal RA. Failure of meglumine antimoniate to cure cutaneous lesions due to Leishmania major in Algeria. Trans R Soc Trop Med Hyg 1986; 80:670-671.
15. El-Safi SH, Peters W, El-Toam B, El-Kadarow A, Evans DA. Studies on the leishmaniases in the Sudan. 2. Clinical and parasitological studies on cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1991; 85:457-464.
16. Gasser RA, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994; 18:83-90.
17. Junaid AJ. Treatment of cutaneous leishmaniasis with infrared heat. Int J Dermatol 1986; 25:470-472.
18. Aram H, Leibovici V. Ultrasound-induced hyperthermia in the treatment of cutaneous leishmaniasis. Cutis 1987; 40: 350-353.
19. Navin TR, Arana BA, Arana FE, DeMerida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimonate (Glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg 1990; 42:43-50.
20. Velasco-Castrejon O, Walton BC, Rivas-Sanchez B, et al. Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico. Am J Trop Med Hyg 1997; 57:309-312.
21. Bassiouny A, Meshad ME, Talaat M, Kutty K, Metawaa B. Cryosurgery in cutaneous leishmaniasis. Br J Dermatol 1982; 107:467-474.
22. Leibovici V, Aram H. Cryotherapy in acute cutaneous leishmaniasis. Int J Dermatol 1986; 25:473-475.
23. Al-Gindan Y, Kubba R, Omer AH, El-Hassan AM. Br J Dermatol 1988; 118:851-854.
24. El Darouti MA, Rubaie SM. Cutaneous leishmaniasis: treatment with combined cryotherapy and intralesional stibogluconate injection. Int J Dermatol 1990; 29:56-59.
25. El-Safi SH, Murphy AG, Bryceson AD, Neal RA. A double-blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment. Trans R Soc Trop Med Hyg 1990; 84:690-691.
26. El-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 1992; 27:227-231.
27. Ben Salah A, Zakraoui H, Zaatour A, et al. A randomized placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995; 53:162-166.
28. Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, Olliaro P. A randomized placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 1995;53:648-651.
29. Larbi EB, Al-Kawajah A, Al-Gindan Y, Jain S, Abahusain A, Al-Zayer A. A randomized double-blind clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in the eastern province of Saudi Arabia. Am J Trop Med Hyg 1995; 52:166-168.
30. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15:323-350.
31. Lopez-Jaramillo P, Ruano C, Rivera J, et al. Treatment of cutaneous leishmaniasis with nitric-oxide donor. Lancet 1998; 351:1176-1177.
32. Davidson RN, Yardley V, Croft SL, Konecny P, Benjamin N. A topical nitric oxide-generating therapy for cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2000; 94:319-322.
33. Soto J, Hernandez N, Mejia H, Grogl M, Berman J. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate. Clin Infect Dis 1995; 20:47-51.
34. Faris RM, Jarallah JS, Khoja TA, Al-Yamani MJ. Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int J Dermatol 1993; 32:610-612.
35. Tallab TM, Bahamdam KA, Mirdad S, et al. Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Int J Dermatol 1996; 35:594-597.
36. Oliveira-Neto MP, Schubach A, Mattos M, da Costa SC, Pirmez C. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil - an area of Leishmania (V.) braziliensis transmission. Int J Dermatol 1997;36:463-468.
37. Cohen HA, Livshin R. Treatment of leishmaniasis nodosa (oriental sore) with intralesionally injected emetine hydrochloride. J Am Acad Dermatol 1987;17:595-599.
38. Dogra J, Lal BB, Misra SN. Dapsone in the treatment of cutaneous leishmaniasis. Int J Dermatol 1986; 25:398-400.
39. Dogra J. A double-blind study on the efficacy of oral Dapsone in cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1991; 85:212-213.
40. Livshin R, Weinrauch L, Even-Paz Z, El-On J. Efficacy of rifampicin and isoniazid in cutaneous leishmaniasis. Int J Dermatol 1987; 26:55-59.
41. Yardley V, Croft SL. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother 1997; 41:752-756.
42. Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 1993; 16:417-425.
43. Martinez S, Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992; 326:741-744.
44. Herwaldt BL, Neva FA, Berman JD. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992; 327:498-499.
45. Velez I, Agudelo S, Hendrickx E, et al. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. Ann Intern Med 1997; 126:232-236.
46. Momeni A, Aminjavaheri M. Treatment of recurrent cutaneous leishmaniasis. Int J Dermatol 1995; 34:129-133.
47. Martinez S, Gonzalez M, Vernaza ME. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clin Infect Dis 1997; 24:165-169.
48. Weinrauch L, Livshin R, El-on J. Ketoconazole in cutaneous leishmaniasis. Br J Dermatol 1987; 117:666-667.
49. Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med 1990; 89:147-155.
50. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:528-534.
51. Singh S, Singh R, Sundar S. Failure of ketoconazole treatment in cutaneous leishmaniasis. Int J Dermatol 1995; 34:120-121.
52. Alsaleh QA, Dvorak R, Nanda A. Ketoconazole in the treatment of cutaneous leishmaniasis in Kuwait. Int J Dermatol 1995; 34:495-497.
53. Ozgoztasi O, Baydar I. A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey. Int J Dermatol 1997; 36:61-63.
54. Albanese G, Giorgetti P, Santagostino L, Crippa D, Sala G. Cutaneous leishmaniasis. Arch Dermatol 1989; 125:1540-1541.
55. Dogra J, Aneja N, Lal BB, Mishra SN. Cutaneous leishmaniasis in India: clinical experience with itraconazole (R51 211 Janssen). Int J Dermatol 1990; 29:661-662.
56. Al-Fouzan AS, Al Saleh QA, Najem NM, Rostom AI. Cutaneous leishmaniasis in Kuwait: clinical experience with itraconazole. Int J Dermatol 1991; 30:519-521.
57. Van den Enden E, van Gompel A, Stevens A, et al. Treatment of cutaneous leishmaniasis with oral itraconazole. Int J Dermatol 1994; 33:285-286.
58. Momeni AZ, Jalayer T, Emamjomeh M, et al. Treatment of cutaneous leishmaniasis with itraconazole. Arch Dermatol 1996; 132:784-786.
59. Bahamdan KA, Tallab TM, Johargi H, et al. Terbinafine in the treatment of cutaneous leishmaniasis: a pilot study. Int J Dermatol 1997; 36:59-60.
60. Gonzalez-Ruperez J, de Morlius MJ, Moreno Carazo A. Remission of localized cutaneous leishmaniasis in a HIV-positive patient using systemic terbinafine. Dermatology 1997; 194:85-86.
61. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341:1795-1800.
62. Soto J, Toledo J, Gutierrez P, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33:E57-E61.
63. Harms G, Chehade AK, Douba M, et al. A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-gamma in the local treatment of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1991; 85:214-216.
64. Arana BA, Navin TR, Arana FE, Berman JD, Rosenkaimer F. Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala. Clin Infect Dis 1994; 18:381-384.